Milestone Pharmaceuticals Inc — Dividend History & Yield (NASDAQ:MIST) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Dividends per share ————— — Dividend yield % ————— — Payout ratio % ————— —

Nouvelles

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

Le système de spray nasal d’Aptar utilisé pour un nouveau traitement contre la TPSV

Milestone remporte l'approbation de la FDA pour le premier spray nasal auto-administré contre les battements cardiaques rapides soudains | Benzinga France

Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST)

TD Cowen relève la note de l’action Milestone Pharmaceuticals à l’achat suite à l’approbation de la FDA

Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment - Slideshow (NASDAQ:MIST) 2025-12-15

Milestone stock soars after FDA approves first self-administered PSVT spray

L’action de Milestone s’envole après l’approbation par la FDA du premier spray auto-administré pour la TPSV